certificate of analysis is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-01-22. Numbers and descriptions here follow the published literature rather than marketing material.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Common supplier description |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water |
| Typical storage | −20 °C, desiccated, dark | For research samples |
| Analytical method | LC-MS/MS | Used for detection and quantification |
| Regulatory status | Prohibited in sport | WADA metabolic modulator class |
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
MS is not considered a hereditary disease, but over 200 genetic variants have been shown to increase its risk. The probability of developing MS is higher in relatives of an affected person, with a greater risk among those more closely related. An identical twin of an affected individual has a 30% chance of developing MS, 5% for a nonidentical twin, 2.5% for a sibling, and an even lower chance for a half-sibling. MS is also more common in some ethnic groups than others. Specific genes linked with MS include differences in the human leukocyte antigen (HLA) system—a group of genes on chromosome 6 that serves as the major histocompatibility complex (MHC). The MHC is involved in how antigens are presented and how abundant different types of T cells are. The MHC allele (genetic variant) HLA-DRB1*15:01 which is present in 30% of the U.S. and Northern European population, produces the strongest association with higher risk of MS. Other allelles related to MHC exhibit a protective effect. The contribution of HLA variants to MS susceptibility has been known since the 1980s, and it has also been implicated in the development of other autoimmune diseases. Genetic variants in autoimmune diseases are typically linked to T cells, but in MS (and lupus), many are linked to B cells too. In general, MS is associated more closely to autoimmune diseases than to other neurodegenerative diseases.
== Technology == HVEC manufactured approximately 471 particle accelerators between 1946 and 1981. Its former European subsidiary, High Voltage Engineering Europa, produced another 93 between 1958 and 2005. Over 25 years, the company's Van de Graaff product lines evolved from 2.5-metre (8.2 ft) compact medical X-ray generators to 24.5-metre (80 ft) tandem accelerators for nuclear physics research. HVEC also developed the insulating core transformer, a new high-voltage direct current generator that found applications in industrial radiation processing. These products enabled commercial development of electron-beam sterilization, radiation crosslinking of polymers, and ion implantation for semiconductor manufacturing.
The four substrates of this enzyme are L-lysine, reduced nicotinamide adenine dinucleotide phosphate (NADPH), oxygen, and a proton. Its products are N(6)-hydroxy-L-lysine, oxidised NADP+, and water. The enzyme is a flavin-containing monooxygenase that uses molecular oxygen as oxidant and incorporates one of its atoms into the starting material. The systematic name of this enzyme class is L-lysine,NADPH:oxygen oxidoreductase (6-hydroxylating). It is also called lysine N6-hydroxylase. It participates in siderophore biosynthesis and uses flavin adenine dinucleotide as a cofactor.
Sources: en.wikipedia.org
Total activity (or just activity), A, is the number of decays per unit time of a radioactive sample. Number of particles, N, in the sample. Specific activity, a, is the number of decays per unit time per amount of substance of the sample at time set to zero (t = 0). "Amount of substance" can be the mass, volume or moles of the initial sample. These are related as follows:
All three ethanolamines are produced in the process, while ammonia and part of methylamine are recycled. The final products are separated by vacuum distillation. Hydroxyalkylamines are produced in a similar process:
He held a very wide variety of posts, included Member, Governing Body, Royal Academy of Music, 1967–1979, Director, Central Statistical Office, 1968–1978, BBC Music Advisory Committee, 1971–1983, Visiting Fellow, Nuffield College, Oxford, 1972–1980, Chairman, Royal Opera House, Covent Garden, 1974–1987, Director, N M Rothschild & Sons, 1978–1990 (Vice-chairman, 1978–1984), President, Royal Statistical Society, 1978–1980, Chairman, Economist Intelligence Unit, 1979–1983, Warden of Wadham College, Oxford, 1984–1993, Chancellor, Keele University, 1986–2002, Trustee, London Philharmonic Orchestra, 1988–2000, President, British Association for the Advancement of Science, 1989–1990, Pro-Vice-Chancellor, University of Oxford, 1991–1993, Chairman, British Museum Development Trust, 1993–2003, later Chairman Emeritus, Chancellor, Open University of Israel, 1994–2004 Moss, Celia (1819-1873 and Marion (1821-1901), Anglo-Jewish writers and educators, authors of poetry, prose and fiction, Marion Moss Hartog established the first Jewish women's periodical, the Jewish Sabbath Journal: A Penny and Moral Magazine for the Young, which foundered after it was attacked by the Jewish Chronicle.
Sources: en.wikipedia.org
Social disorganization theory is intended to be applied to neighborhood level street crime, thus the context of gang activity, loosely formed criminal associations or networks, socioeconomic demographic impacts, legitimate access to public resources, employment or education, and mobility give it relevance to organized crime. Where the upper- and lower-classes live in close proximity this can result in feelings of anger, hostility, social injustice and frustration. Criminals experience poverty; and witness affluence they are deprived of and which is virtually impossible for them to attain through conventional means. The concept of neighborhood is central to this theory, as it defines the social learning, locus of control, cultural influences and access to social opportunity experienced by criminals and the groups they form. Fear of or lack of trust in mainstream authority may also be a key contributor to social disorganization; organized crime groups replicate such figures and thus ensure control over the counter-culture. This theory has tended to view violent or antisocial behavior by gangs as reflective of their social disorganization rather than as a product or tool of their organization.
== History == Setipiprant was initially researched by Actelion as a treatment for allergies and inflammatory disorders, particularly asthma, but despite being well tolerated in clinical trials and showing reasonable efficacy against allergen-induced airway responses in asthmatic patients, it failed to show sufficient advantages over existing drugs and was discontinued from further development in this application. However, following the discovery in 2012 that the prostaglandin D2 receptor (DP/PGD2) is expressed at high levels in the scalp of men affected by male pattern baldness, the rights to setipiprant were acquired by Kythera to develop the drug as a novel treatment for baldness. The favorable pharmacokinetics and relative lack of side effects seen in earlier clinical trials mean that fresh clinical trials for this new application can be conducted fairly quickly. As of 2015, setipiprant is currently under development by Allergan for the prevention of androgenic alopecia after their successful acquisition of Kythera.
=== "Last dictators" advertisement === In 2011, Nando's launched a "Last dictators" advert in South Africa. The 60-second commercial shows a sad Robert Mugabe dining alone at Christmas in a large mansion while he reminisces about "happier times" with former dictators, such as playing water tag with Muammar Gaddafi, singing karaoke with Mao Zedong, making snow angels in the sand with Saddam Hussein, pushing P. W. Botha on a swing set, and riding a Covenanter cruiser tank with Idi Amin in a similar fashion to Leonardo DiCaprio and Kate Winslet embracing each other from the film Titanic, while the music from "Those Were the Days" is played. Musekiwa Kumbula, holder of the Nando's franchise in Zimbabwe, said his group "strongly feels the advertisement is insensitive and in poor taste." The advert also offended Chipangano, a Zimbabwean youth militia loyal to Mugabe, who then demanded an apology from Nando's, threatened to boycott the South Africa-based chain, and demanded the advert be withdrawn or the restaurant face retribution. Nando's South Africa subsequently withdrew the advert citing threats to its staff in Zimbabwe from a youth group.
Sources: en.wikipedia.org
Legality depends on the country and the intended use. In many places it is sold as a research chemical, but sports and medicine regulations restrict it.
Detection commonly uses liquid chromatography–tandem mass spectrometry. This method can identify the compound in urine or blood at low concentrations.
Typical guidance is −20 °C, dry, and protected from light. Solutions should be aliquoted and limited freeze–thaw cycles should be used.
It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.